Skip to content

Based on my review of the GO-CAM model and all the available information, I will now provide a comprehensive evaluation of gomodel:6348a65d00002600:

Review of GO-CAM Model: gomodel:6348a65d00002600

Model Overview

This GO-CAM model titled "Negative regulation of white adipogenesis by OVOL2. (Human)" represents a biological pathway where OVOL2 (Ovo-like zinc finger 2) negatively regulates white adipogenesis. The model is based on human data and has a "production" status.

Model Components

The model consists of four main activities: 1. OVOL2 (Q9BRP0) - Transcription corepressor activity (GO:0003714) 2. CEBPA (P49715) - DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228) 3. SLC2A4/GLUT4 (P14672) - D-glucose transmembrane transporter activity (GO:0055056) 4. FABP4 (P15090) - Long-chain fatty acid transmembrane transporter activity (GO:0005324)

The model describes how OVOL2 negatively regulates CEBPA, which in turn positively regulates both SLC2A4 and FABP4, leading to white fat cell proliferation.

Causal Relationships

The model contains three causal associations: 1. OVOL2 directly negatively regulates (RO:0002630) CEBPA 2. CEBPA provides input for (RO:0002407) SLC2A4 3. CEBPA provides input for (RO:0002407) FABP4

Evidence Assessment

The model is supported by appropriate evidence, primarily from PMID:36228616, which describes OVOL2's role in suppressing white adipogenesis by blocking CEBPA binding to its transcriptional targets. The model also references PMID:12556481 and PMID:12077340 as supporting evidence for specific relationships.

Strengths of the Model

  1. Biological accuracy: The model correctly represents OVOL2's role in inhibiting white adipogenesis as described in the primary literature (PMID:36228616).
  2. Proper protein-protein interaction representation: The interaction between OVOL2 and CEBPA is correctly modeled, with OVOL2 directly inhibiting CEBPA's transcriptional activity.
  3. Appropriate downstream targets: The model correctly identifies FABP4 and GLUT4 as downstream targets of CEBPA in the adipogenesis pathway.
  4. Correct causal relationships: The causal relationships (negative regulation of CEBPA by OVOL2 and positive regulation of FABP4/GLUT4 by CEBPA) align with the literature.

Issues and Recommendations

  1. Minor evidence issue: Evidence statements appear to be appropriate, but the annotation linking FABP4 to GO:0005324 (long-chain fatty acid transmembrane transporter activity) cites transfer from mouse ortholog (P04117) via ECO:0000250. While FABP4 does indeed bind and transport fatty acids, suggesting it acts as a fatty acid transporter, the evidence would be stronger with direct experimental evidence in human cells.

  2. Improvement opportunity: The model could be enhanced by including additional molecular details about how OVOL2 inhibits CEBPA, such as:

  3. The physical interaction between OVOL2's zinc finger domains and CEBPA's bZIP domain

  4. The mechanism by which this interaction prevents CEBPA binding to DNA targets

  5. Model completeness: The model could be expanded to include:

  6. Additional downstream targets of CEBPA in the adipogenesis pathway
  7. The role of PPARĪ³, which is mentioned in the literature as an important player in adipogenesis

  8. The thermogenic function of OVOL2 in brown/beige adipocytes, which is also described in PMID:36228616

  9. Cellular contextualization: The model would benefit from including cellular components for all activities, such as specifying that OVOL2 and CEBPA activities occur in the nucleus.

Conclusion

Overall, gomodel:6348a65d00002600 is a high-quality GO-CAM model that accurately represents the negative regulation of white adipogenesis by OVOL2 through inhibition of CEBPA transcriptional activity. The model adheres to GO-CAM best practices for representing protein activities and causal relationships. It is supported by appropriate evidence from the literature, particularly PMID:36228616, which provides detailed molecular insights into OVOL2's dual role in promoting thermogenesis and limiting white adipogenesis.

The model could be improved by providing more molecular detail about the OVOL2-CEBPA interaction, expanding the representation of the adipogenesis pathway, and adding cellular context information. However, these are suggestions for enhancement rather than corrections of errors, as the model is fundamentally accurate in its current form.